PRO DEX INC (PDEX): Quarter Ended June 30, 2026
PRO DEX INC (PDEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2026 FOURTH QUARTER AND FULL-YEAR RESULTS IRVINE, CA, September 3, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) t oday announced financial results for i
How this was made
The 30-second read
Why it matters
The earnings beat and margin improvement provide a fresh catalyst for traders, while expense growth tempers enthusiasm.
Market read
First‑time earnings disclosure for a micro‑cap medical device company, offering a modest trading opportunity.
What to watch
Volatility from marketable equity investments and integration risks of the APM acquisition.
Background
Pro‑Dex, a Nasdaq Capital Market listed medical device maker, filed its quarterly earnings via an 8‑K filing.
Ticker impact
SEC Form 8‑K reports Pro‑Dex's Q4 and full‑year 2026 results, showing 17% revenue growth and a 35% gross margin.
Potential short‑term price rally of 5‑8% if market digests the beat.
First‑time disclosure of earnings with solid top‑line growth and improved margins provides actionable insight.
Market effects
Positive earnings may boost sentiment in the medical device and orthopedic equipment sector.
Limited to U.S. small‑cap market; no broader regional effect.
Minimal global impact beyond niche medical device investors.
Counterpoint
Higher operating expenses and reliance on a single large customer could pressure margins if demand wanes.
Key entities
- ExecutiveRichard L. Van Kirk
CEO of Pro‑Dex who commented on the results.
- SubsidiaryAdvanced Precision Machining, LLC (APM)
Recent acquisition contributing to revenue and expenses.